<DOC>
	<DOC>NCT00912405</DOC>
	<brief_summary>This study allows continued access to the Sinexus Intranasal Splint while a marketing application is being prepared. This study will generate additional performance, reimbursement and safety data for the steroid-eluting Sinexus Intranasal Splint when used following Functional Endoscopic Sinus Surgery (FESS) in patients with chronic sinusitis (CS).</brief_summary>
	<brief_title>Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Patient is 18 years of age or older Patient has a diagnosis of chronic sinusitis Patient has a clinical indication for and has consented to FESS Patient CT scan confirms CS diagnosis within 6 months of procedure CT sacn confirms presence of disease in ethmoid sinus(es) Planned FESS includes unilateral or bilateral total ethmoidectomy Immune deficiency (IGG subclass deficiency or IGA deficiency) Oralsteroid dependent COPD, asthma or other condition Clinical evidence of acute bacterial sinusitis History or diagnosis of glaucoma or ocular hypertension Clinical evidence or suspicion of invasive fungal sinusitis Evidence of disease or condition expected to compromise survival or ability to complete followup Known history of allergy or intolerance to corticosteroids History of insulin dependent diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Patients diagnosed with Chronic Sinusitis undergoing functional endoscopic surgery (FESS)</keyword>
</DOC>